BeloGal® platform is applicable for lung-targeted delivery of Meropenem

The first step of the biodistribution study of Belopenem in rats has been successfully completed.

Double Bond Pharmaceutical combined the BeloGal®platform with the well-known antibiotic Meropenem, giving rise to two working Belopenem formulations. The recent study showed a superior lung-targeted delivery of Meropenem through the formulations, when compared to the standard intravenous Meropenem solution. The study is expected to be completed in December 2019 – January 2020.

“I am very glad that we are able to validate the BeloGal®platform for lung-targeting of an additional API – Meropenem. We believe that it will result in the development of novel treatments of different lung diseases and with that, provide a bright hope for patients”, says Igor Lokot, the CEO of Double Bond Pharmaceutical.

The study is being conducted in a frame of EuroStar project (https://news.cision.com/se/dbp/r/dbp-har-beviljats-eurostars-finansiering-for-utveckling-av-en-ny-produkt-for-behandling-av-lunginfla,c2576018 )

More about BeloGal®: BeloGal® is DBP’s innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver.

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 26 of September 2019. 

____________________________________________________________________ 

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:     DBP B

Share ISIN code:         SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

Tags:

Subscribe

Documents & Links